Publicacions en col·laboració amb investigadors/es de Hospital Clínico San Carlos de Madrid (7)

2020

  1. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis

    Hepatology, Vol. 72, Núm. 6, pp. 1924-1934

2019

  1. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

  2. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience

    Journal of Viral Hepatitis, Vol. 24, Núm. 6, pp. 464-471

2015

  1. Actualización terapéutica en la hepatitis C

    Revista Espanola de Quimioterapia, Vol. 28, pp. 48-51

2012

  1. Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma

    Oncology, Vol. 82, Núm. 1, pp. 35-40

2008

  1. "12 Weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label?

    Scandinavian Journal of Gastroenterology, Vol. 43, Núm. 8, pp. 979-983